PDS Biotech Announces Publication of VERSATILE-002 Phase 2 Clinical Trial Results of PDS0101 with pembrolizumab in HPV16-Positive Recurrent and/or Metastatic (R/M) Head and Neck Cancer in JAMA Oncolog

Go back to PDS Biotech Announces Publication of VERSATILE-002 Phase 2 Clinical Trial Results of PDS0101 with pembrolizumab in HPV16-Positive Recurrent and/or Metastatic (R/M) Head and Neck Cancer in JAMA Oncolog
(NASDAQ: PDSB) Delayed: 1.17 -0.07 (5.65%)
Previous Close $1.24    52 Week High $ 
Open $1.16    52 Week Low $ 
Day High $1.22    P/E N/A 
Day Low $1.12    EPS $ 
Volume 3,535,471